Q BioMed Inc
Change company Symbol lookup
Select an option...
QBIO Q BioMed Inc
FRZA Forza X1 Inc
ILMN Illumina Inc
NR Newpark Resources Inc
CGC Canopy Growth Corp
NAOV Nanovibronix Inc
ETON Eton Pharmaceuticals Inc
LXRX Lexicon Pharmaceuticals Inc
BVS Bioventus Inc
TDS-U Telephone and Data Systems Inc

Health Care : Biotechnology |
Company profile

Q BioMed Inc. is a biotech acceleration and commercial stage company. The Company is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. The Company’s pipeline products include Strontium89, QBM-001, Uttroside-B, and MAN 01. Strontium89 treats pain from bone metastases caused by multiple primary tumors. Strontium Chloride Sr-89 Injection, USP is indicated for the relief of bone pain in patients with painful skeletal metastases. QBM-001 is designed to alleviate the condition and allow toddlers to actively develop language and speech and avoid life-long speech and intellectual disabilities caused from being non-verbal. Uttroside-B is a potential chemotherapeutic for liver cancer. Its primary indication, MAN-01, is for the treatment of primary open angle glaucoma, wherein it is developing a small molecule in the form of an easy to administer eye drop to reduce intra-ocular eye pressure (IOP), a key risk factor in the progression of glaucoma.

Closing Price
Day's Change
-0.0031 (-28.18%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.